Immune Design to Present at Upcoming September Investor Conferences
August 30 2018 - 8:00AM
Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on
novel therapies in oncology, today announced that senior management
will present at the following upcoming investor conferences:
13th Annual Wells Fargo Securities Healthcare
ConferenceWednesday, September 5, 2018 at 1:50 p.m.
Eastern Time in Boston.
H.C. Wainwright & Co. 20th Annual Global Investment
ConferenceThursday, September 6, 2018 at 10:50 a.m.
Eastern Time in New York.
A live webcast of each presentation will be available online
from the investor relations page of the company's corporate website
at http://ir.immunedesign.com/events.cfm . After the live webcast,
an archive of each presentation will be available on the company
website for 30 days.
About Immune Design
Immune Design is a late-stage immunotherapy
company employing next-generation in vivo approaches to enable the
body's immune system to fight disease. The company's technologies
are engineered to activate the immune system's natural ability to
generate and/or expand antigen-specific cytotoxic immune cells to
fight cancer and other chronic diseases. CMB305 and G100, the
leading product candidates with broad potential in oncology, are
based on the company’s two technology platforms that are potent
stimulators of the immune system: ZVex® and GLAAS®. Both ZVex
and GLAAS also have potential applications in infectious disease
and allergy indications, which are being developed through ongoing
pharmaceutical collaborations. Immune Design has offices in
Seattle and South San Francisco. For more information, please visit
www.immunedesign.com.
Media ContactJulie
RathbunRathbun Communicationsjulie@rathbuncomm.com
206-769-9219
Investor ContactSylvia
WheelerSylvia.wheeler@immunedesign.com
IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Historical Stock Chart
From Apr 2023 to Apr 2024